The data suggest that the antitumor effects of PD-L1 blockade therapy in CT26 colorectal tumor model are associated with a reduction in tumor-infiltrating PD-L1+ immune cells, but not the number of intratumoral T cells. Here, CD274 is linked to colorectal neoplasm.